Advances In™ PAH Associated with Congenital Heart Disease (PAH-CHD): Designing New Treatment Strategies Backed by Better Disease Understanding
October 12, 2021
October 12, 2022
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
This online educational activity is directed toward cardiologists, pulmonologists, NPs, PAs, and RNs. Additional healthcare professionals involved in the management and treatment of patients with PAH-CHD will also be invited to participate in this activity.
Pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) is a lethal and progressive disease in which prostacyclin, nitric oxide, and endothelin-1 pathways are disturbed and contribute to the pathophysiology of this disease. Undiagnosed or delayed diagnosis of PAH might lead to Eisenmenger syndrome (ES). Screening for PAH in patients with CHD and timely diagnosis can facilitate prompt treatment; promising medical therapies have recently been approved for the management of patients with PAH-CHD, bringing about hope for improved hemodynamics, exercise capacity, quality of life, and possibly, survival for this patient population.
Upon completion of this activity, participants should be better able to:
- Describe the latest theories of PAH-CHD pathogenesis
- Discuss advances in the diagnostic and prognostic assessment of PAH-CHD
- Determine appropriate treatment strategies for individual patients based on disease pathophysiology, disease severity, and risk assessments
Richard Channick, MD
Professor of Medicine
UCLA David Geffen School of Medicine
Co-Director, Pulmonary Vascular Disease Program
UCLA Medical Center
Los Angeles, CA
Vallerie McLaughlin, MD
Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine
Associate Chief Clinic Officer, Cardiovascular Service Line, UMMG
Associate Chief, Division of Cardiovascular Medicine
Director, Inpatient Services
Director, Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
Richard Channick, MD
- Grant/Research Support: Janssen, Gossamer Bio; Consultant: Janssen, Bayer, Third Pole Therapeutics, Gossamer Bio, United Therapeutics
- Speaker's Bureau: Janssen, Bayer
Vallerie McLaughlin, MD
- Grant/Research Support: Acceleron, Janssen, Sanofi, United Therapeutics
- Consultant: Acceleron, Aerovate Therapeutics, Altavant, Bayer, Caremark, CiVi BioPharma Inc., CorVista Health, Gossamer Bio, Janssen, Merck, United Therapeutics
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.